Overview
Over the years, Biocon Biologics has grown into a leading global biosimilars player, enabling affordable access to life-saving medicines and transforming patients’ lives across the world.
We have a broad pipeline of 20 biosimilar molecules spanning insulins, monoclonal antibodies and conjugated recombinant proteins, out of which nine are commercialized products. Direct commercial presence in advanced and emerging markets take us closer to patients, payors and healthcare systems, and strengthen our position as a global biosimilars player. We have listed below the regions where we have commercial presence.
For information about our products country wise, please select your country from the Product Locator page.
Global Footprint That Extends in 120+ Countries Across Advanced and Emerging Markets
Civica’s mission is to help people who need access to necessary generic and biosimilar medicines at affordable prices. This includes people living with diabetes, one in five of whom have skipped, delayed, or used less insulin than was needed to save money. Our partnership with Biocon Biologics for Aspart drug substance supply will allow us to deliver on our important mission and help people who need access to Insulin Aspart.”
Ned McCoy, President and Chief Executive Officer, Civica, Inc
Civica’s mission is to help people who need access to necessary generic and biosimilar medicines at affordable prices. This includes people living with diabetes, one in five of whom have skipped, delayed, or used less insulin than was needed to save money. Our partnership with Biocon Biologics for Aspart drug substance supply will allow us to deliver on our important mission and help people who need access to Insulin Aspart.”
Ned McCoy, President and Chief Executive Officer, Civica, Inc
I started on your Hulio product a few weeks ago and have had 2 doses…. I just wanted to tell you how happy I am. I have not been this comfortable in years. I am delighted! Thank you for your and your colleagues’ amazing attention to all of this! I would never have been able to navigate through the maze.
A patient in Canada, who is suffering from an autoimmune disease
I started on your Hulio product a few weeks ago and have had 2 doses…. I just wanted to tell you how happy I am. I have not been this comfortable in years. I am delighted! Thank you for your and your colleagues’ amazing attention to all of this! I would never have been able to navigate through the maze.
A patient in Canada, who is suffering from an autoimmune disease
Biosimilars are increasingly being adopted (in Brazil) as first-line therapies owing to their strong outcomes. However, the high treatment costs limit broader access…. Biocon Biologics’ market entry intensifies competition, helping reduce biologics' prices and improving patient access. For the pharmaceutical industry, this marks a critical inflection point, a maturing biosimilar landscape with rising demand and pressure for cost containment.”
Professor Stephen Stefani, Clinical Oncologist and Professor of Health Technology Assessment and Health Economics at Fundação Unimed, Brazil.
Biosimilars are increasingly being adopted (in Brazil) as first-line therapies owing to their strong outcomes. However, the high treatment costs limit broader access…. Biocon Biologics’ market entry intensifies competition, helping reduce biologics' prices and improving patient access. For the pharmaceutical industry, this marks a critical inflection point, a maturing biosimilar landscape with rising demand and pressure for cost containment.”
Professor Stephen Stefani, Clinical Oncologist and Professor of Health Technology Assessment and Health Economics at Fundação Unimed, Brazil.
Related Links
Biocon Biologics has nine biosimilars commercialized globally directly or through its partners. We are serving over 5 million patients in...
